Tiziana's Intranasal Foralumab Shows Consistent Neuroinflammation Reduction in MSA Patients — Tiziana Life Sciences Ltd.

Event summary

Tiziana reported a 34% reduction in standardized uptake value (SUV) and 26% reduction in SUVR in the brain regions affected by Multiple System Atrophy (MSA) after treating the third patient with intranasal foralumab.
The results are consistent with previous findings from the first two MSA patients, showing up to 35% reduction in SUV and 24% reduction in SUVR.
Tarun Singhal of Brigham and Women’s Hospital noted the consistency of PET findings across patients, reinforcing the biological activity of intranasal foralumab in reducing neuroinflammation.
Tiziana plans to continue evaluating intranasal foralumab in additional MSA patients to further validate these findings.

The big picture

Tiziana's intranasal foralumab represents a novel approach to modulating the immune system through mucosal tolerance mechanisms, potentially offering a safer and more effective treatment for neuroinflammatory and neurodegenerative diseases. The consistent reduction in neuroinflammation across multiple MSA patients underscores the therapeutic potential of this fully human anti-CD3 monoclonal antibody, positioning Tiziana as a key player in the biotech space focused on innovative drug delivery technologies.

What we're watching

Clinical Validation: Whether the consistent PET scan results will translate into meaningful clinical improvements for MSA patients.
Regulatory Pathway: The pace at which Tiziana can advance intranasal foralumab through further clinical trials and potential regulatory approvals.
Market Differentiation: How Tiziana positions intranasal foralumab against existing treatments for neurodegenerative diseases, given the lack of approved disease-modifying options for MSA.